Nationwide Pharmaceutical Litigation and Wrongful Death Lawyers

ETHEX Corporation recently announced a recall of specific lots of five generic drugs it manufactures due to the potential that oversized tablets, which may contain more than twice the listed dosage, have been distributed to consumers. Possible side effects from excessive dosages of the recalled drugs include heart, respiratory, and blood pressure disorders.

The U.S. Food and Drug Administration issued a press release on November 7, 2008, confirming that ETHEX had voluntarily recalled multiple lots of various dosages of its “Propafenone HCl Tablets,” “Isosorbide Mononitrate Extended Release Tablets,” “Morphine Sulfate Extended Release Tablets,” “Morphine Sulfate Immediate Release Tablets” and “Dextroamphetamine Sulfate Tablets” If you or any of your loved ones have been prescribed any of these drugs, contact your physician immediately.

Excessive dosages of any of these drugs can create serious health problems. Overdoses of Propafenone HCl may cause arrhythmia (irregular heartbeat) and low blood pressure. Excessive Isosorbide Mononitrate may cause fainting and low blood pressure. Too much Morphine Sulfate may cause respiratory depression (difficulty or lack of breathing) and low blood pressure. Symptoms of excessive Dextroamphetamine Sulfate include rapid heart rate and high blood pressure.

If you or someone you know has taken any of these medications or currently has a supply of these drugs, call us immediately for information about the recall and about the potential for recovering monetary damages for illnesses and/or  injuries associated with the ETHEX Corporation recall.

The ETHEX Corporation issued a voluntary recall of five generic products due to the possibility that oversized tablets may be found in some of the lots. Oversized tablets pose the risk of patients taking more than double the prescribed dose and associated side effects. In some cases, such side effects can be life threatening.

The drugs of concern are Propafenone HCI, Isosorbide Mononitrate, Morphine Sulfate and Dextroamphetamine Sulfate. Overdose of Propafenone HCI can lead to arrhythmias (irregular heartbeat) and low blood pressure. Isosorbide Mononitrate overdose can cause fainting and low blood pressure. Morphine Sulfate overdose may lead to respiratory depression and low blood pressure. Dextroamphetamine overdose complications can include rapid heart rate and high blood pressure.

All lots were shipped prior to May 22, 2008. The tablet and Lot number descriptions are as follows:

Propafenone HCl Tablets, 150 mg: Lots: 73761, 78184, 79373, 81240, 81241, 81242, 83470, 84357, 90525, and 90526 with expiration dates ranging from 3/2009 to 3/2011

Propafenone HCl Tablets, 225 mg: Lots: 71720, 74831, 76014-15, 81243-45, 89731, 90527-29, and 90657 with expiration dates ranging from 3/2009 to 2/2011

Propafenone HCl Tablets, 300 mg: Lots: 72834, 76016-18, 81246, 89092, 89732, 90530, 90532, and 91641-42 with expiration dates ranging from 6/2009 to 3/2011

Isosorbide Mononitrate Extended Release Tablets, 30 mg: Lots: 62355, 66423, and 68102 with expiration dates ranging from 11/2008 to 8/2009

Isosorbide Mononitrate Extended Release Tablets, 60 mg: Lots: 63466, 66034, 67351, and 67354 with expiration dates ranging from 12/2008 to 11/2009

Morphine Sulfate Extended Release Tablets, 15 mg: Lots: 81175, 82514-16, 89660, 89664, 89667, 90249-51, and 91687 with expiration dates ranging from 12/2008 to 2/2010

Morphine Sulfate Immediate Release Tablets, 15 mg: Lots: 77852-54, 81746, 82519-20, 84113, and 90276-78 with expiration dates ranging from 9/2009 to 1/2011

Morphine Sulfate Immediate Release Tablets, 30 mg: Lots: 75093, 77855-57, 82297, 82521-22, 87239, 88925, and 90288-98 with expiration dates ranging from 8/2009 to 3/2011

Dextroamphetamine Sulfate Tablets, 10 mg: Lots: 73934, 75892, 77945, 81137, 86320 with expiration dates ranging from 6/2009 to 5/2011

The 150 mg Propafenone Hydrochloride Tablets is a white, scored round film coated tablet with “ETH” on one side and “331″ with a bisect on the reverse. The 225 mg Propafenone Hydrochloride Tablets is a white, scored round film coated tablet with “ETH” on one side and “332″ with a bisect on the reverse. The 300 mg Propafenone Hydrochloride Tablets is a white, scored round film coated tablet with “ETH” on one side and “333″ with a bisect on the reverse.

The 30 mg Isosorbide Mononitrate Extended Release Tablet is an oval, reddish-pink, film-coated tablet with a debossed “E” bisecting “30″ on one side and bisect on the other side. The 60 mg Isosorbide Mononitrate Extended Release Tablet is an oval, yellow film-coated tablet with a debossed “E” bisect “60″ on one side and bisect on the other side.

The 15 mg Morphine Sulfate Extended Release Tablet is a green oval tablet with “15″ on one side and an “E” on the reverse. The 15 mg Morphine Sulfate Immediate Release Tablet is a round brown tablet with a “15″ on one side and an “ETH” on the reverse. The 30 mg Morphine Sulfate Immediate Release Tablet is a capsule shaped brown tablet with “30″ on one side and an “ETHEX” on the reverse.

The 10 mg Dextroamphetamine Sulfate Tablet is a round, flat-face, bevel edge, orange mottled tablet debossed “ETHEX” and “312″ on one side and double-scored on the other side.

Distributors and retailers have been notified of the recall and instructed to return the products and notify consumers. The products will be replaced or refunded. Consumers are urged to contact the ETHEX consumer inquiry number, pharmacist, or health care provider. Any adverse reactions should also be reported to the FDA.

ETHEX Customer Service: 1-800-748-1472. Fax ETHEX Customer Service at 314-646-3751 or Email: customer-service@ethex.com. Representatives available Monday through Friday, 8:00 am to 5:00 pm Central Standard Time (CST).

FDA’s MedWatch Program:1-800-FDA-1088, Fax at 1-800-FDA-0178, mail at MedWatch, FDA, 5600 Fishers Lane, Rockville, MD 20852-9787, or the MedWatch website at www.fda.gov/medwatch.

Do I Have an ETHEX Recall Lawsuit?

If you or somebody you know has been injured by drugs manufactured by ETHEX Corporation, you should contact us immediately.  You may be entitled to compensation for your injuries and Scott Nabers, Esq. can help.

Pharmaceutical manufacturer Ethex Corp has announced a voluntary recall of five consumer products, all of which were shipped before May 22nd, 2008. The company has reported that these medications may have twice their normal dosage due to oversized capsules.

Propafenone HCI, Isosorbide Mononitrate (extended release), Morphine Sulfate (extended and immediate release), and Dextroamphetamine Sulfate, the drugs associated with the recall, can cause serious side effects if taken in higher-than-recommended doses.

If you or a loved one has been injured by any of the above drugs, do not hesitate to contact an attorney – you may be entitled to monetary compensation.

Ethex Corp. has recalled several lots containing shipments of these prescription medications, citing the possibility that some tablets could contain higher levels of their drug’s active ingredient.

Ingestion of the recalled pharmaceuticals can result in a number of potentially dangerous side effects. Side effects associated with Propafenone HCI are irregular heartbeat and low blood pressure, while the effects of Isosorbide Mononitrate may include fainting as well as low blood pressure. Overdose of Morphine Sulfate may result in low blood pressure and difficulty or lack of breathing, and overdose of Dextroamphetamine can induce side effects such as rapid heart rate and high blood pressure.

If you or a family member have used any of these medications and believe that you have experienced adverse effects on your life or health, help is a phone call away. Please contact our attorneys as soon as possible and fight for your rights as a patient.

November 2008

As a precautionary measure, the Ethex Corporation recently recalled particular lots of five of their generic products on the market. The products are as follows:

Dextroamphetamine Sulfate Tablets- 10 mg
Propafenone HCI tablets- 150 mg, 225 mg, and 300 mg
Isosorbide Mononitrate Extended Release Tablets- 30mg and 60 mg
Morphine Sulfate Extended Release Tablets- 15 mg
Morphine Sulfate Immediate Release Tablets- 15 mg and 30 mg

The concern is that some of tablets may be oversized, which means they may contain more of the active ingredient than was initially intended. Patients who consume the oversized tables would receive twice the normal amount of the drug and overdoses of any of the aforementioned drugs could be very serious and/or life threatening.

The Ethex Corporation has notified all retailers and wholesalers who have received the particular lots of each drug and both retailers and wholesalers have received specific instructions on how to return all of the oversized tablets. Pharmacies were also instructed to contact all of their customers that had received the product and customers are to receive a refund and/or a replacement of the drug.

If you or a loved one has recently taken the aforementioned tablets and are experiencing any of the following signs or symptoms, contact your doctor or healthcare provider without delay.

Propafenone HCEL: irregular heartbeat and low blood pressure
Isosorbide Mononitrate: fainting and low blood pressure
Morphine Sulfate Extended and Immediate Release: respiratory difficulties (trouble breathing) and low blood pressure
Dextroamphetamine Sulfate: rapid heart rate and high blood pressure

Customers interested in more information, can call the Ethex Customer Service Department for more information: Ethex Customer Service 1-800-748-1472

The specific lots that were recalled, all shipped prior to May 22, 2008, are listed below.

Dextroamphetamine Sulfate Tablets- 10 mg: Lots 73934, 75892, 77945, 81137, 86320. The expiration dates can be anywhere from June 2009 to May 2011.

Propafenone HCI tablets- 150 mg: Lots: 73761, 78184, 79373, 81240, 81241, 81242, 83470, 84357, 90525, and 90526. The expiration dates can be anywhere from March 2009 to March 2011.

Propafenone HCI tablets- 225 mg: Lots: 71720, 74831, 76014-15, 81243-45, 89731, 90527-29, and 90657. The expiration dates can be anywhere from March 2009 to February 2011.

Propafenone HCI tablets- 300 mg: Lots: 72834, 76016-18, 81246, 89092, 89732, 90530, 90532, and 91641-42. The expiration dates can be anywhere from June 2009 to March 2011.

Isosorbide Mononitrate Extended Release Tablets- 30mg: Lots: 62355, 66423, and 68102. The expiration dates can be anywhere from November 2008 to August 2009

Isosorbide Mononitrate Extended Release Tablets- 60mg: Lots: 63466, 66034, 67351, and 67354. The expiration dates can be anywhere from December 2008 to November 2009

Morphine Sulfate Extended Release Tablets- 15 mg: Lots: 81175, 82514-16, 89660, 89664, 89667, 90249-51, and 91687. The expiration dates can be anywhere from December 2008 to February 2010.

Morphine Sulfate Immediate Release Tablets- 15 mg : Lots: 77852-54, 81746, 82519-20, 84113, and 90276-78. The expiration dates can be anywhere from September 2009 to January 2011.

Morphine Sulfate Immediate Release Tablets- 30 mg: Lots: 75093, 77855-57, 82297, 82521-22, 87239, 88925, and 90288-98. The expiration dates can be anywhere from August 2009 to March 2011.

If you or a loved one have experienced any serious side effects, you may be entitled to compensation for your injuries.  Please use the form below to have your potential ETHEX recall case evaluated by an experienced drug side effects and drug recall attorney / lawyer.

The FDA has announced that the ETHEX Corporation has voluntarily recalled five generic, non-branded products. ETHEX has taken this step as a precaution, for the drugs may contain oversized tablets. Oversized tablets can cause a drug overdose because they contain more than the intended levels of the active ingredient. This could result in the patient receiving as much as double the expected dosage of the drug.

Consumers who experience any adverse reactions to these drugs should contact their physician and/or healthcare provider immediately.

The current recall pertains to the following drugs:

Propafenone HCl Tablets, 150 mg: Lots: 73761, 78184, 79373, 81240, 81241, 81242, 83470, 84357, 90525, and 90526 with expiration dates ranging from 3/2009 to 3/2011. Tablets are white tablet with “ETH” on one side and “331″ on the reverse.

Propafenone HCl Tablets, 225 mg: Lots: 71720, 74831, 76014-15, 81243-45, 89731, 90527-29, and 90657 with expiration dates ranging from 3/2009 to 2/2011. Tablets are white, with “ETH” on one side and “332″ on the reverse.

Propafenone HCl Tablets, 300 mg: Lots: 72834, 76016-18, 81246, 89092, 89732, 90530, 90532, and 91641-42 with expiration dates ranging from 6/2009 to 3/2011. Tablets are white, with “ETH” on one side and “333″ on the reverse.

Isosorbide Mononitrate Extended Release Tablets, 30 mg: Lots: 62355, 66423, and 68102 with expiration dates ranging from 11/2008 to 8/2009. Tablets are an oval, reddish-pink tablet, with a debossed “E” “30″ on one side and bisect on the other side.

Isosorbide Mononitrate Extended Release Tablets, 60 mg: Lots: 63466, 66034, 67351, and 67354 with expiration dates ranging from 12/2008 to 11/2009. Tablets are an oval, yellow tablet with a debossed “E” “60″ on one side and bisect on the other side.

Morphine Sulfate Extended Release Tablets, 15 mg: Lots: 81175, 82514-16, 89660, 89664, 89667, 90249-51, and 91687 with expiration dates ranging from 12/2008 to 2/2010. Tablet is a green oval tablet with “15″ on one side and an “E” on the reverse.

Morphine Sulfate Immediate Release Tablets, 15 mg: Lots: 77852-54, 81746, 82519-20, 84113, and 90276-78 with expiration dates ranging from 9/2009 to 1/2011. Tablet is a round brown tablet with a “15″ on one side and an “ETH” on the reverse.

Morphine Sulfate Immediate Release Tablets, 30 mg: Lots: 75093, 77855-57, 82297, 82521-22, 87239, 88925, and 90288-98 with expiration dates ranging from 8/2009 to 3/2011. Tablet is a capsule shaped brown tablet with “30″ on one side and an “ETHEX” on the reverse.

Dextroamphetamine Sulfate Tablets, 10 mg: Lots: 73934, 75892, 77945, 81137, 86320 with expiration dates ranging from 6/2009 to 5/2011. Tablets are a round, orange mottled tablet debossed “ETHEX” and “312″ on one side and double-scored on the other side.

Recall notifications have been issued to all ETHEX wholesalers and retailers who were shipped any inventory of the recalled lots. These notifications include instructions for returning the recalled products and instructions for retailers and/or pharmacies to contact consumers who were issued these drugs for replacement and/or refund.

Wholesalers and retailers are urged to contact ETHEX Customer Service at 1-800-748-1472 in regards to procedures for returning the recalled products. Also, if consumers have any questions about the recall they should call ETHEX Customer Service, their physician, and pharmacist or any other health care provider. Consumers, wholesalers and retailers can also fax to EHEX Customer Service at 314-646-3751 or email customer-service@ethex.com. Representatives are available Monday through Friday 8:00 AM to 5:00 PM CST.

Consumers who experience any adverse reactions to these drugs should contact their physician and/or healthcare provider immediately.

The ETHEX Corporation recall is being conducted with the knowledge of the U.S. Food and Drug Administration (FDA).

Customers, wholesalers or retailers may also contact FDA’s MedWatch Program by phone at 1-800-FDA-1088, by Fax at 1-800-FDA-0178, by mail at MedWatch, FDA, 5600 Fishers Lane, Rockville, MD 20852-9787, or on the MedWatch website at www.fda.gov/medwatch in regards to any adverse reactions experienced with the use of these products, or any other problems.

Do I Have a Lawsuit?

If you or a loved one have experienced an adverse event or serious side effect you should also contact a drug side effects or drug recall attorney immediately.  You may be entitled to compensation for your injuries and we can help.  Please use the form below for a free case evaluation.

The ETHEX Corporation has recently announced a voluntarily recall of five specific lots of generic products that it currently markets. These lots may contain possibly hazardous oversized tablets, and as a result, a recall is being undertaken as a precaution. Oversized tablets pose certain health risks, as they can contain excess levels of the active drug ingredient. Ingesting such tablets could result in patients consuming up to nearly twice the expected dosage of the drugs.

The lots that are the subject of this recall were all shipped before May 22, 2208. These lots include:

Propafenone HCl Tablets, 150 mg: Lots: 73761, 78184, 79373, 81240, 81241, 81242, 83470, 84357, 90525, and 90526 with expiration dates ranging from March, 2009 to March, 2011. An overdose of this drug can have serious and/or life-threatening consequences, which may include irregular heartbeat (arrhythmias), and decreased blood pressure. These tablets are white and have a coated, scored round film with “ETH” on one side and “331″ with on the other.

Propafenone HCl Tablets, 225 mg: Lots: 71720, 74831, 76014-15, 81243-45, 89731, 90527-29, and 90657 with expiration dates ranging from March, 2009 to February, 2011. These tablets look very similar to the Propafenone 150 mg tablets, except they read “332” on the side opposite the “ETH” letters. These tablets have the same health consequences explained for the Propafenone 150 mg tablets.

Propafenone HCl Tablets, 300 mg: Lots: 72834, 76016-18, 81246, 89092, 89732, 90530, 90532, and 91641-42 with expiration dates ranging from June, 2009 to March, 2011. These tablets are, again, white with a coated, scored round film. The letters “ETH” on one side and on the 300 mg tablet, “333″ appears on the reverse. These tablets have the same health consequences explained for the Propafenone 150 mg tablets.

Isosorbide Mononitrate Extended Release Tablets, 30 mg: Lots: 62355, 66423, and 68102 with expiration dates ranging from November, 2008 to August, 2009. Ingestion of these oversized tablets may result in fainting and/or low blood pressure. These tablets are oval and film colored with a reddish-pink color. An “E” dividing “30″ appears on one side, with a bisect on the other.

Isosorbide Mononitrate Extended Release Tablets, 60 mg: Lots: 63466, 66034, 67351, and 67354 with expiration dates ranging from December, 2008 to November, 2009. Theses tablets are oval and film-coated, are yellow in color and include an “E” dividing “60″ on one side and bisect on the other. These tablets have the same health consequences explained for the Isosorbide 30 mg tablets.

Morphine Sulfate Extended Release Tablets, 15 mg: Lots: 81175, 82514-16, 89660, 89664, 89667, 90249-51, and 91687 with expiration dates ranging from December, 2008 to February, 2010. An overdose of the drugs contained in these tablets can have serious or life-threatening consequences. Such consequences can include respiratory depression characterized by difficulty or lack of breathing and low blood pressure. These tablets are green and oval with a “15″ on one side and an “E” on the other.

Morphine Sulfate Immediate Release Tablets, 15 mg: Lots: 77852-54, 81746, 82519-20, 84113, and 90276-78 with expiration dates ranging from September, 2009 to January, 2011. These tablets are round and brown colored and contain a “15″ on one side and an “ETH” on the other. These tablets have the same health consequences explained for the Morphine Sulfate 15 mg tablets.

Morphine Sulfate Immediate Release Tablets, 30 mg: Lots: 75093, 77855-57, 82297, 82521-22, 87239, 88925, and 90288-98 with expiration dates ranging from August, 2009 to March, 2011. These tablets are capsule shaped and brown colored, and contain a “30″ on one side and an “ETHEX” on the other. These tablets have the same health consequences explained for the Morphine Sulfate 15 mg tablets.

Dextroamphetamine Sulfate Tablets, 10 mg: Lots: 73934, 75892, 77945, 81137, 86320 with expiration dates ranging from June, 2009 to May, 2011. An overdose of this drug can have serious and life-threatening consequences, such as rapid heart rate and high blood pressure. These tablets are round, flat-faced, bevel edged, orange-colored mottled tablets with “ETHEX” and “312″ on one side and are double-scored on the other.

ETHEX Corporation has sent recall notifications to both retailers and wholesalers who have received any inventory of the recalled lots. This notification provides instructions to return the drugs, and also includes instructions for the retailers/pharmacies to contact the consumers who received these drugs for replacement and/or refund of the product. If consumers have any questions about this recall, they should contact their physician, their pharmacist or other health care provider, and strongly consider obtaining the guidance of  legal counsel to preserve their legal rights to the extent they exist.

Consumers who experience any adverse reactions to these drugs should contact their physician and/or healthcare provider immediately. Affected consumers should also immediately contact an attorney as damages may be recoverable.

ETHEX Corporation has issued a voluntary nationwide recall of five generic drug product tablets. There is a possibility that oversized tablets may have been released. Such tablets may contain higher levels of the active drug ingredient. The recalled tablets are Propafenone HCl Tablets of 150 mg, 225 mg and 300 mg; Isosorbide Mononitrate Extended Release Tablets of 30 mg and 60 mg; Morphine Sulfate Extended Release Tablets of 15 mg; Morphine Sulfate Immediate Release Tablets of 15 mg and 30 mg; Dextroamphetamine Sulfate Tablets of 10 mg.

The increased strength tablets can cause serious harm. Propafenone HCI can lead to low blood pressure and arrhythmias, or an irregular heartbeat. Isosorbide Mononitrate can cause low blood pressure and fainting. Morphine Sulfate can lead to low blood pressure and respiratory recession, including the difficulty or lack of breathing. Dextroamphetamine Sulfate can cause high blood pressure and an increased heart rate.

Only certain lots of the tablets have been recalled. All recalled lots were shipped before May 22, 2008.

If you or a member of your family has suffered the aforementioned side effects from taking any of the listed drugs, you should contact us immediately. We may be able to help you and offer a free case evaluation.

Breaking News: ETHEX Corporation has issued a voluntary recall of five generic/non-branded products it markets. These consumer level specific lots are being recalled because they may contain oversized tablets, which could result in patients receiving double the expected dosage. If you are taking any of the drugs listed below and experience an adverse reaction, contact your physician immediately, as an overdose could have serious or life-threatening consequences.

The following products involved in the recall were all shipped prior to May 22, 2008:

Propafenone HCl Tablets - 150 mg, 225 mg, and 300 mg can cause arrhythmias (irregular heartbeat) and low blood pressure

Isosorbide Mononitrate Extended Release Tablets – 30 mg and 60 mg can cause fainting and low blood pressure

Morphine Sulfate Extended Release Tablets - 15 mg can cause respiratory depression (difficulty or lack of breathing) and low blood pressure

Morphine Sulfate Immediate Release Tablets - 15 mg and 30 mg can cause respiratory depression (difficulty or lack of breathing) and low blood pressure

Dextroamphetamine Sulfate Tablets - 10 mg can cause rapid heart rate and high blood pressure

Do I Have a Lawsuit? If you or a loved one has been injured by any of the products listed above, you should contact an attorney immediately. You may be entitled to compensation for your injuries and we can help.

ETHEX Corporation has voluntarily recalled specific lots of five generic products that it markets. These lots may consist of oversized tablets and may contain more than the intended levels of the active ingredient. Patients taking these oversized tablets may receive as much as twice the intended dosage of these drugs.

An overdose of these active ingredients may result in serious consequences, specifically - where an overdose of Propafenone HCL is involved, patients may experience irregular heartbeats and low blood pressure; those taking higher doses of Isosorbide Mononitrate are prone to fainting and low blood pressure; a Morphine Sulphate overdose may cause the patient to experience difficulties breathing as well as low blood pressure; and finally, an overdose of Dextroamphetamine Sulfate increases the risk of rapid heart rate and high blood pressure.

The lots involved in the recall were all shipped prior to May 22, 2008 and are described as follows:

Propafenone HCl Tablets, 150 mg:
White, scored round film coated tablet with “ETH” on one side and “331” with a bisect on the reverse
Lots: 73761, 78184, 79373, 81240, 81241, 81242, 83470, 84357, 90525, and 90526
Expiration dates ranging from 03/2009 to 03/2011

Propafenone HCl Tablets, 225 mg:
White, scored round film coated tablet with “ETH” on one side and “332” with a bisect on the reverse
Lots: 71720, 74831, 76014-15, 81243-45, 89731, 90527-29, and 90657
Expiration dates ranging from 03/2009 to 02/2011

Propafenone HCl Tablets, 300 mg:
White, scored round film coated tablet with “ETH” on one side and “333” with a bisect on the reverse
Lots: 72834, 76016-18, 81246, 89092, 89732, 90530, 90532, and 91641-42
Expiration dates ranging from 06/2009 to 03/2011

Isosorbide Mononitrate Extended Release Tablets, 30 mg:
Oval, reddish-pink, film coated tablet with a debossed “E” bisecting “30” on one side and a bisect on the reverse
Lots: 62355, 66423, and 68102
Expiration dates ranging from 11/2008 to 08/2009

Isosorbide Mononitrate Extended Release Tablets, 60 mg:
Oval, yellow film-coated tablet with a debossed “E” bisecting “30” on one side and a bisect on the reverse
Lots: 63466, 66034, 67351, and 67354
Expiration dates ranging from 12/2008 to 11/2009

Morphine Sulfate Extended Release Tablets, 15 mg:
Green oval tablet with “15” on one side and an “E” on the reverse
Lots: 81175, 82514-16, 89660, 89664, 89667, 90249-51, and 91687
Expiration dates ranging from 12/2008 to 02/2010

Morphine Sulfate Immediate Release Tablets, 15 mg:
Brown, round tablet with a “15” one side and an “ETH” on the reverse
Lots: 77852-54, 81746, 82519-20, 84113, and 90276-78
Expiration dates ranging from 09/2009 to 01/2011

Morphine Sulfate Immediate Release Tablets, 30 mg:
Capsule shaped brown tablet with a “30” on one side and an “ETHEX” on the reverse
Lots: 75093, 77855-57, 82297, 82521-22, 87239, 88925, and 90288-98
Expiration dates ranging from 08/2009 to 03/2011

Dextroamphetamine Sulfate Tablets, 10 mg:
Orange, round, flat-face, bevel edge, mottled tablet with an “ETHEX” and “312” on one side and double-scored on the reverse
Lots: 73934, 75892, 77945, 81137, 86320
Expiration dates ranging from 06/2009 to 05/2011

Patients believing they may have taken the above lots should contact their physician immediately for medical advice.

If you believe that you or a loved one has suffered serious injury or death as a result of ingesting these generic drugs, contact an attorney immediately. You may be legally entitled to compensation for medical expenses, lost wages, and compensation for pain and suffering or physical impairment.

Digitek/digoxin is a drug prescribed primarily for patients diagnosed with abnormal heart rhythms or heart failure. Actavis Group, an Icelandic pharmaceutical company, manufactures Digitek, the generic version of digoxin  The drug is distributed by Mylan Pharmaceuticals, Inc under the label “Bertek,” and by UDL Laboratories Inc., under the label “UDL.” Digitek/digoxin was recently recalled due to the issuance of double-strength tablets which can cause Digitalis toxicity.

If you or a loved one have been injured by Digitek/digoxin, you should contact an attorney immediately.  You may be entitled to compensation for your injuries and we can help.

Digitalis toxicity can result in serious side effects including nausea, vomiting, bradycardia, dizziness, low blood pressure, cardiac instability, even death.  Serious side effects and illness have been reported by Digitek users due to Digitalis toxicity.

Again, if you or a loved one have been injured by Digitek/digoxin, you may be entitled to compensation for those injuries as well as costs you may incur for monitoring actual and potential injuries in the future.